Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings PharmaCorp Rx Inc.: Strengths and Weaknesses

Highlights: PharmaCorp Rx Inc.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: PharmaCorp Rx Inc.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • With an expected P/E ratio at 49 and 16.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

PharmaCorp Rx Inc. SectorCanada

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

-

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

PharmaCorp Rx Inc. SectorCanada

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

PharmaCorp Rx Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

PharmaCorp Rx Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

-

Rating Revisions

PharmaCorp Rx Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
60.57M - - - -
15.05B
AA
5.91B
AAA
3.9B
AAA
3.22B
BBB
3.09B
BB
2.96B
AAA
2.63B - - - - -
2.56B -
BBB
- -
1.51B
AAA
-
Average 4.09B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PCRX Stock
  4. Ratings PharmaCorp Rx Inc.